Allogene Therapeutics Inc (ALLO)vsInsmed Inc (INSM)
ALLO
Allogene Therapeutics Inc
$2.44
+17.87%
HEALTHCARE · Cap: $465.19M
INSM
Insmed Inc
$136.00
-5.56%
HEALTHCARE · Cap: $29.32B
Smart Verdict
WallStSmart Research — data-driven comparison
ALLO leads profitability with a 0.0% profit margin vs -210.5%. INSM earns a higher WallStSmart Score of 39/100 (F).
ALLO
Avoid27
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 152.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
0.0% earnings growth
Trading at 39.4x book value
ROE of -249.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALLO
The strongest argument for ALLO centers on Price/Book.
Bull Case : INSM
The strongest argument for INSM centers on Revenue Growth. Revenue growth of 152.6% demonstrates continued momentum. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ALLO
The primary concerns for ALLO are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
ALLO profiles as a value stock while INSM is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 152.6% — sustainability is the question.
ALLO generates stronger free cash flow (-28M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100) and 152.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Allogene Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?